A class of medications called cholinesterase inhibitors help to turn back the clock on Alzheimer’s disease’s cognitive symptoms. More than a third people over…
Alzheon’s new Alzheimer’s ALZ-801 drug is finishing up recruiting for Phase 3 clinical trials. If the trial proves successful, it may become the first…
Here’s a theory: Alzheimer’s biomarker beta-amyloid could — rather than killing the brain — actually be trying to defend it. The provocative idea builds on…
Biogen and Eisai’s next disease-modifying Alzheimer’s drug candidate, lecanemab, has been granted FDA priority review, signaling that a decision could be made by early…
European drug regulators dealt a blow to Biogen, deciding against allowing Aduhelm onto the market. Meanwhile, the company slashed the price of its drug…
Viagra may also reduce the risk of developing Alzheimer’s or dementia. While this link isn’t causative, the new research opens the door for clinical…
The FDA will hasten the review of two more new Alzheimer’s drug candidates, Eli Lilly & Co.’s donanemab and Biogen and Eisai’s lecanemab. Today,…